Details

Autor(en) / Beteiligte

• Loras, Carme
• Ruiz-Ramirez, Pablo
• Romero, Juan
• Andújar, Xavier
• Bargallo, Josep
• Bernardos, Esther
• Boscá-Watts, Marta Maia
• Brugiotti, Carlo
• Brunet, Eduard
• Busquets, David
• Cerrillo, Elena
• Co
• Díaz-Milanés, Juan Antonio
• Dueéas, Carmen
• Farrés, Ramón
• Golda, Thomas
• González-Huix, Ferran
• Gornals, Joan B
• Guardiola, Jordi
• Julià, David
• Lira, Alba
• Llaó, Jordina
• Maéosa, Miriam
• Marin, Ingrid
• Millán, Mónica
• Monfort, David
• Moro, David
• Mullerat, Josep
• Navarro, Mercè
• Pérez Roldán, Francisco
• Pijoan, Eva
• Pons, Vicente
• Reyes, José
• Rufas, María
• Sainz, Empar
• Sanchiz, Vicente
• Serracant, Anna
• Sese, Eva
• Soto, Cristina
• Troya, Jose
• Zaragoza, Natividad
• Tebé, Cristian
• Paraira, Marta
• Sudrià-Lopez, Emma
• Mayor, Vicenç
• Fernández-Baéares, Fernando
• Esteve, Maria

Titel

Endoscopic treatment : an open-label, multicentre, randomized trial

Ist Teil von

• Trials, 2023-06, Vol.24 (1)

Ort / Verlag

BioMed Central Ltd

Erscheinungsjahr

2023

Quelle

Springer Journals

Beschreibungen/Notizen

• Background Stenosis is one of the most common complications in patients with Crohn's disease (CD). Endoscopic balloon dilation (EBD) is the treatment of choice for a short stenosis adjacent to the anastomosis from previous surgery. Self-expandable metal stents (SEMS) may be a suitable treatment option for longer stenoses. To date, however, there is no scientific evidence as to whether endoscopic (EBD/SEMS) or surgical treatment is the best approach for de novo or primary stenoses that are less than 10 cm in length. Methods/design Exploratory study as "proof-of-concept", multicentre, open-label, randomized trial of the treatment of de novo stenosis in the CD; endoscopic treatment (EBD/SEMS) vs surgical resection (SR). The type of endoscopic treatment will initially be with EDB; if a therapeutic failure occurs, then a SEMS will be placed. We estimate 2 years of recruitment and 1 year of follow-up for the assessment of quality of life, costs, complications, and clinical recurrence. After the end of the study, patients will be followed up for 3 years to re-evaluate the variables over the long term. Forty patients with de novo stenosis in CD will be recruited from 15 hospitals in Spain and will be randomly assigned to the endoscopic or surgical treatment groups. The primary aim will be the evaluation of the patient quality of life at 1 year follow-up (% of patients with an increase of 30 points in the 32-item Inflammatory Bowel Disease Questionnaire (IBDQ-32). The secondary aim will be evaluation of the clinical recurrence rate, complications, and costs of both treatments at 1-year follow-up. Discussion The ENDOCIR trial has been designed to determine whether an endoscopic or surgical approach is therapeutically superior in the treatment of de novo stenosis in CD. Trial registration ClinicalTrials.gov NCT 04330846. Registered on 1 April 1 2020. Keywords: Crohn's disease, De novo or primary stenosis, Endoscopic treatment, Balloon dilation, Self-expandable metal stent, Surgical resection, Randomized clinical trial, Proof-of-concept study